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Abstract
In the span of just 11 years since their discovery, the study of the orexins (hypocretins) has not only
provided insight into the biology of sleep/wakefulness, but also demonstrated the importance of the
development of new pharmacologic tools and genetic models with which to understand basic
physiologic mechanisms and provide potential strategies for the treatment of human pathologies.
Highlights from recently published novel approaches and findings are reviewed here.
Introduction and context
Discovered almost simultaneously by two independent
groups, orexin A and orexin B (also known as hypocre-
tin-1 and hypocretin-2) are post-translational products
of a gene expressed almost exclusively in neurons of the
hypothalamus [1,2], where functionally distinct subpo-
pulations of orexin neurons have been hypothesized to
reside [3]. Orexin neurons in the lateral hypothalamic
area have been suggested to be important in hunger and
reward, while those in the dorsomedial hypothalamus
are more related to arousal state [3]; however, their exact
roles remain open for debate [4]. Two cognate receptors
have been identified, orexin type 1 receptor (OX1R),
which couples primarily via a Gq/11, and orexin type 2
receptor (OX2R), which couples via Gi or Gq/11, and
perhaps a Gs protein. In addition to their originally
described orexigenic actions, the peptides act pharma-
cologically to increase arousal [5,6], elevate sympathetic
tone [7,8], stimulate the neuroendocrine mechanisms
controlling stress hormone secretion [9-12], and activate
reward pathways [3]. However, their hallmark actions,
which are clearly physiologic in nature, are related to
sleep/wakefulness [13]. Compromises in the production
of orexin or OX2R result in a behavioral phenotype
similar to human narcolepsy/cataplexy [14,15] and
indeed many human cases of narcolepsy appear to be
the result of selective degeneration of orexin-producing
neurons in the lateral hypothalamic/perifornical area of
the brain [16].
Major recent advances
The potential for therapeutic use of orexin or orexin
analogs to treat the debilitating symptoms of narcolepsy
has driven the study of these pluripotent peptides. In the
process, much has been learned about more than simply
the biology of sleep/wakefulness; many novel
approaches for their study have been developed. One
that cannot adequately be discussed here is the
innovative use of genetic targeting of the channelrho-
dopsin-2 gene to orexin (hypocretin) neurons followed
by optogenetic photostimulation, which resulted in clear
evidence that the orexin (hypocretin)-producing neurons
control the transition to wakefulness from slow wave
and rapid eye movement (REM) sleep [17]. It is
impossible in a brief review to cite inclusively all the
outstanding manuscripts in the field. Instead, the current
focus is on two or three biologic effects of the peptides,
recent advances in the study of those actions, and the
innovative approaches employed by investigators in the
field to elucidate the full biologic spectrum and potential
therapeutic uses of the orexins. For more comprehensive
coverage of the subject, the readers may consult a recent,
excellent review by one of the peptides’ discoverers,
T Sakurai [13].
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Deletion of the orexin gene results in an animal with a
behavioral phenotype similar to human narcolepsy/
cataplexy [14]. Similarly, compromise of the OX2R gene
[15] produces a narcoleptic/cataplectic phenotype. In
normal rats, central administration of a selective OX2R
ligand enhanced wakefulness while reducing REM and
non-REM sleep [18]. An innovative approach to the
identification of the orexin receptor subtype responsible
for maintenance of wakefulness was recently employed
by Shiromani and colleagues [19]. They identified OX2R
expression in enhanced green fluorescent protein-posi-
tive GABAergic (g-aminobutyric acid-producing) neu-
rons of the ventrolateral periaquaductal gray (vlPAG) of
a transgenic animal and then targeted those neurons for
destruction using a saporin hypocretin-2 (orexin B)
conjugate. This not only identified the vlPAG as a
potential site of action for the arousal effects of orexin,
but also demonstrated the importance of the OX2R in the
inhibitory control of REM sleep. Additional experiments
in this excellent manuscript suggest the importance of
the vlPAG in the action of the orexins is limited to REM
sleep, but that it is not a substrate for the cataplexy of
orexin absence.
Is there hope for development of a therapeutic strategy
for orexin replacement?
In humans degeneration of orexin-producing neurons
can cause narcolepsy/cataplexy [16]. Thus, the full
phenotype of human narcolepsy might require loss of
the orexin-producing neuron, and consequently the
absence of not only orexin, but also co-localized
peptides like galanin, dynorphin, or neuronal activity-
related pentraxin. For this reason Yanagisawa and
colleagues developed the orexin-ataxin-3 transgenic
mouse and rat models [20,21], in which, over time, the
orexin-producing neurons degenerate and the behavioral
phenotype eventually appears. Proof that the behavior
was due to the loss of orexin came in studies using these
animals with subsequent central administration of high
doses of orexin or ectopic expression in brain of a prepro-
orexin transgene [22]. Thus, it appeared possible that
ligands selective for OX2R might be developed that could
cross the blood-brain-barrier and replace the missing
endogenous orexin, rescuing the phenotype. However,
with the exception of one report in nonhuman primates
[23], little evidence for therapeutic penetration of
peripherally administered orexin has been forthcoming.
An alternative would be gene transfer within brain. Proof
of concept was recently published by Liu et al.[24]. Using
a replication defective herpes simplex virus-1 amplicon-
based vector, these authors transferred the gene encoding
orexin into the lateral hypothalamus of orexin knockout
mice. They demonstrated transient neuronal expression
and, importantly, a temporally correlated improvement
of the behavioral phenotype. As the authors openly
conclude, gene transfer worked in the orexin knockout
mice, where orexin expression has been lost but not the
orexin-producing neurons. The technique now needs to
be applied to the more relevant animal model, the
orexin-ataxin-3 transgenic mouse (or rat), in which the
orexin-producing neurons have been lost, just as is the
case for the brains of humans suffering from narcolepsy/
cataplexy.
What about the opposite side of the coin?
Could orexin antagonists be used to treat insomnia?
Almorexant, a dual OX1R/OX2R antagonist has been
demonstrated to act after peripheral administration to
promote sleep in a variety of species, including humans
[25]. Recently, Dugovic and colleagues [26] demon-
strated that the effects of almorexant were in all likelihood
due to the compound’s ability to block OX2R, as similar
sleep-promoting effects (decreased latency for persistent
sleep and increased non-REM and REM sleep time) were
observed in rats treated with a selective OX2R antagonist.
What other effects of orexin might appear during
therapeutic use of agonists or antagonists of the receptors?
As mentioned already, the orexins are pluripotent
neuromodulators. Two areas of current research point
to impressive additional actions of the peptides. Orexin
knockout mice not only demonstrate a narcoleptic
phenotype, but also with aging develop obesity, which
at first seems counterintuitive since the peptide pharma-
cologically stimulates food intake. Indeed, knockout
mice eat less but gain more weight than age-matched
wild-type mice. Once again, the Yanagisawa and Sakurai
labs have employed state of the art genetic approaches to
examine this apparent paradox [27]. They have demon-
strated recently that transgenic overexpression of orexin
protects against high-fat-diet-induced obesity, and the
attendant insulin insensitivity, by promoting energy
expenditure. Surprisingly, these mice actually ate less as
well. Combining the genetic background of the orexin
overexpressing transgene with either OX1Ro rO X 2R
knockout animals, these authors demonstrated that
OX2R is essential for the prevention of diet-induced
obesity. Leptin sensitivity was also improved in these
animals. This may indicate the important interaction of
metabolic cues and orexin, as might be predicted from
the intriguing findings of Burdakov and colleagues [28]
that orexin neurons in lateral hypothalamus respond
directly to fluctuating levels of plasma and cerebrospinal
fluid glucose. Thus, selective activation of OX2Ri n
humans may not only ameliorate the sleep disturbances
of orexin cell loss, but also alleviate some of the
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type of many narcoleptic humans [29].
Can manipulation uniquely of the OX1R be rewarding?
Finally, much interest has been generated in the
possibility that the orexins play an important role in
reward behaviors [3]. Orexin appears to influence
morphine-induced place preference [30]. A role for
OX1R in reward/addictive behaviors has been demon-
strated by these authors as well [3]. Antagonism of OX1R,
but not OX2R, decreased cue-induced cocaine seeking,
following extinction or abstinence [31]. Thus, one could
envision the potential use of orexin antagonists for the
modification of reward-based behaviors [3]. However,
OX1R has also been implicated as the receptor mediating
the autonomic and neuroendocrine actions of the
orexins [12] and, therefore, selectivity of effect may be
a difficult issue to control. The realization of the
important actions of the orexins on reward-based and
addictive behaviors may provide insight into the
neuronal mechanisms responsible for the expression of
those behaviors.
Is arousal the overriding effect of the orexins or can the
peptides exert biological actions independent of
arousal state?
Another way of stating the question would be: is the
orexigenic action of the peptide secondary to arousal? If
so, why do orexin knockout mice become obese even
though they eat less? We were never overly impressed by
the magnitude of food consumption observed in our
ad libitum fed rats following orexin administration, but
we were impressed by the sympatho-stimulatory effects
of those doses and the increases in spontaneous
locomotor activity that ensued [5,6,8]. Are the increased
autonomic function and locomotor activities a reflection
of activation of stress pathways in the brain [9-12]? Does
activation of stress pathways initially induce and
subsequently suppress food intake? It is clear from the
outstanding work of Yanagisawa and colleagues [27] that
“…orexin gain of function promotes energy expenditure
while loss of function promotes energy conservation”.A s
those authors speculated [27], the sympatho-stimulatory
action of the orexins may partly explain those
observations.
Future directions
Clearly the development of orally active orexin analogs is
a goal of many investigators. However, the simple fact
that the orexins are ‘pluripotent’ neuropeptides raises
design problems that may prove daunting, if not
insurmountable. While some antagonists are in devel-
opment, the manipulation of central orexin levels has, to
date, been limited to direct administration or transgenic
delivery. Orexin analogs for therapeutic usage must have
receptor selectivity especially when targeting OX2R, since
activation of OX1R, at least in experimental animals,
causes a stress response (i.e., elevated mean arterial
pressure and stress hormone secretion). The promise of
application of OX2R selective ligands for the treatment of
metabolic syndrome is great, but again bioavailability
and selectivity are major hurdles to be cleared. Will these
orexin analogs be of clinical value for addiction therapies
and eating disorders? Here too, selectivity will be an
issue. In any case, the study of orexin biology has been
and still is opening many new insights into human
physiology and driving the development of novel
scientific approaches.
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